Fresenius Kabi is a global healthcare company founded in 1912, employing more than 43,000 people across operations in over 100 countries. The company specialises in essential products and services for infusion, transfusion, and clinical nutrition therapies, serving critically and chronically ill patients. Its reach extends to nearly 450 million patients annually, operating across hospitals, long-term care facilities, home care settings, and blood banks.
The company's portfolio is organised into four business segments. Pharma covers injectable drugs and IV therapy. Biopharma focuses on biosimilars for autoimmune diseases and oncology. Nutrition provides parenteral and enteral nutrition products. MedTech encompasses infusion systems, blood collection devices, and cell and gene therapy technologies.
Technical domains span infusion systems, transfusion technologies, clinical nutrition, biosimilars, and advanced therapies including cell and gene therapy. The company operates under its Vision 2026 and #FutureFresenius strategy, with a focus on developing, producing, and selling innovative products and technologies.
